Nexsen Limited (NXN.AX)
ASX · AUD · Healthcare · Biotechnology
A$0.16 (-3.03%) as of
Key statistics
- Market cap
- 32.32M
- EPS (TTM)
- -0.0400
- Dividend yield
- 0.00%
- 52-week range
- 0.1050 – 0.3450
- Profit margin
- 0.00%
- Volume
- 132.05k
About Nexsen Limited
Nexsen Limited operates as a nanobiotechnology company that develops proprietary biosensing platforms for rapid, high-precision point-of-care (POC) medical diagnostics and point-of-use sensing for human health, food and animal health, and biosecurity applications. The company offers Group B Streptococcus (GBS) rapid sensor; StrepSure, a diagnostic for the detection of human GBS in expectant mothers; kidney diseases, a POC tests for the screening, detection, and ongoing monitoring of various subsets of acute kidney injury and chronic kidney disease; bovine mastitis, a farm diagnostic to detect mastitis early which helps farmers; biosecurity pathogen tests, a portable sensor for frontline detection of invasive pests and pathogens -built for customs officers, farmers, and quarantine zones. It also offers rapid diagnostic programs targeting traumatic brain injury and neonatal sepsis. In addition, it is involved in developing rapid dual sensors for the detection of E.coli and Salmonella. The company was incorporated in 2021 and is based in Sydney, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Sydney, NSW, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.